MedTrace Logo

Stunning in Takotsubo Versus Acute Myocardial Infarction

NCT04448639 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 125

Last updated 2023-12-12

No results posted yet for this study

Summary

The Stunning in Takotsubo versus Acute Myocardial Infarction (STAMI) Study

Background: Acute myocardial stunning, herein defined as the reversible loss of myocardial function, occurs in both takotsubo syndrome (TS) and ST-elevation myocardial infarction (STEMI), and can be life-threatening in both conditions. However, despite typically having considerably more pronounced myocardial stunning, TS patients have better prognosis than patients with STEMI. Despite the different relationship between extent of myocardial stunning and prognosis in TS vs STEMI, no 'head-to-head' comparison of the myocardial stunning phenotypes in TS vs STEMI has been done.

Methods: The Stunning In Takotsubo and Acute Myocardial Infarction (STAMI) study is a single-center, prospective clinical study that will enroll 100 patients with STEMI and 25 patients with TS. Echocardiography, laboratory testing (including troponin and NTpro-BNP), and ECG will be done immediately after angiography and at days 1, 2, 3, 7, 14 and 30. The primary endpoint is the proportion of myocardial stunning that has resolved after 72 hours, as determined by echocardiography. Total myocardial stunning is defined as the extent of akinesia observed at day 0 that resolves by day 30.

Conditions

  • Myocardial Stunning

Interventions

DIAGNOSTIC_TEST

Echocardigraphy (ECHO)

Standar 12 lead electrocardiogram

DIAGNOSTIC_TEST

Bloodtest

cardiac biomarkers

Sponsors & Collaborators

  • Vastra Gotaland Region

    lead OTHER_GOV

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-12
Primary Completion
2024-01-31
Completion
2030-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04448639 on ClinicalTrials.gov